InvestSMART

Genesis Research & Development Corporation Limited (ASX: GEN2) - Share Price

DELISTED

GEN2 General Information +

ASX Code GEN2
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) n/a
GEN2 Share Price N/A
Day High N/A
Day Low N/A
Last Close N/A
GEN2 Share Price Movement N/A
+Security prices are delayed by at least 20 minutes and are indicative only.

Genesis Research & Development Corporation Limited (GEN2) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Genesis Research & Development Corporation Limited (GEN2) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Genesis Research & Development Corporation Limited (GEN2) Recent ASX Announcements

There are no announcements from Genesis Research & Development Corporation Limited (GEN2). Please use our ASX Announcements tool to search for announcements across all ASX-listed securities.

GEN2 Directors

Name Position Start Date
Mr Stephen Hall Company Secretary, Chief Executive Officer 17 Dec 2004
Mr Gude Buer Executive Director 19 Dec 2012
Mr Joachim(Aki) Herbert von Roy Non-Executive Chairman 17 Jun 2005
Dr Steven Gillis Non-Executive Director 2 Dec 1993
Dr Andrew (Andy) John Hubert Gearing Non-Executive Director 26 Jan 2006
Mr Daniel Mahnert-Lueg Non-Executive Director 14 Mar 2011
Mr Christopher Manie Non-Executive Director 8 Feb 2013
Ms Sharon Kwan Non-Executive Director 8 Aug 2013
Mr Frankie Chen Non-Executive Director 8 Aug 2013
Mr Phi San Lam Non-Executive Director 8 Aug 2013

Genesis Research & Development Corporation Limited (GEN2) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value

See all changes in directors' interest & trades for Genesis Research & Development Corporation Limited (GEN2) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

GEN2 Management

Name Position
Gregory (Greg) Murison Chief Scientific Officer
Diana Gash Head of Clinical and Regulatory Affairs
Anand Kumble Head of Product Development

GEN2 Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in -- (GEN2). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
7,437,941 (16.35%) UBNZ Funds Management Limited
4,427,435 (9.70%) Bagnall, Nicholas Stuart
4,370,000 (9.60%) Accident Compensation Corporation

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.